The overview discusses 58 peptides in various clinical phases, indicating a sturdy pipeline of peptide therapies targeting PPIs. Any prospective conflicts of fascination, including funding from pharmaceutical organizations or private investments in related industries, are totally disclosed within the research publications. This disclosure is cri